RNA-derived medicines: a review of the research trends and developments

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

RNA-derived medicines: a review of the research trends and developments

Sponsored by

Logo 22.07.22.png
Coronavirus RNA strand. Medical illustration. 3D rendering

CAS considers how the emerging field of RNA therapeutics highlights trends in targets, chemical modifications, and new delivery systems that increase stability of RNA

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine. RNA technology provides an innovative approach to developing drugs against difficult or challenging therapeutic targets, holding potential across many diseases ranging from the largest global health challenges to extremely rare diseases.

However, RNA medicine has faced many challenges: RNA molecules are relatively unstable and transient, the limited translation into cellular protein expression can hinder efficacy, and foreign RNA molecules often trigger immunogenicity. Furthermore, the delivery of RNA molecules can be a challenge due to their relatively large size and high electric charge.

Some of these practical problems can be mitigated by chemically modifying the RNA, providing the opportunity to develop therapeutics that are more stable, effective, and tolerable for patients. The recent success of mRNA vaccines against COVID-19 and the approval of new RNA-based drugs has provided new momentum to the field, building on the key milestones and achievements of the last 60 years. Advances in our understanding of RNA structure and function, combined with a robust production pipeline, have substantially increased the capacity to develop clinically effective RNA-related applications.

In this white paper, CAS used data from the CAS Content CollectionTM—the largest human-curated collection of published scientific knowledge—to review publication trends in RNA research, the application of RNA in medicine and the use of chemical modifications and nanotechnology to improve the delivery and efficacy of RNA pharmaceuticals. The white paper focuses on chemical modifications to the nucleic acid base, backbone, and sugar molecules to increase RNA stability, along with the new delivery systems that are critical to the success of RNA medicine.

Click here to access CAS’s white paper – “RNA-derived medicines: a review of the research trends and developments”

Click here to access CAS’s content hub on Managing IP

more from across site and SHARED ros bottom lb

More from across our site

Florina Firaru discusses making new connections, the art of flower arranging, and the biggest misconception about IP
The firm, which appointed three IP partners from A&O Shearman, wants to develop a tier one practice in Europe
The England and Wales appeals court handed down its judgment just seven working days after hearing the trademark dispute involving pharma company Merck
A host of law firms from across Europe and beyond helped bring the streaming technology dispute to a close
Hugues Derème, director general of the Benelux IP Office, unveils his vision for the region, how to improve IP awareness, and use of AI
A copyright win for AI firm Anthropic and a new executive order against law firm Jenner & Block were also among the top talking points this week
A principal at Schwegman Lundberg & Woessner explains how AI tools, including DeepIP, can position the firm to help clients
The firm explains why AI-empowered data analytics could make it a more efficient advocate for its clients
Penelope Aspinall, of IP wellbeing charity Jonathan’s Voice, explains why managers should take a three-tiered approach to looking after workers’ mental health
Heath Hoglund talks about the value proposition of patent pools and why it went ahead with its first-ever series of pool meetings in China
Gift this article